Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.60 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.60 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.60 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.60 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | RHOC | P08134 | 1/20 | 0.58 |
| ▸ | RHOA | P61586 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492831 | 0.82 | PTGS1 (0.70) | MAPTKCNK3KCNK9KCNQ3KCNQ2 | |
| SCHEMBL14468045 | 0.82 | MEN1 (0.68) | MAPTKCNK3KCNK9KCNQ3KCNQ2 | |
| SCHEMBL2497820 | 0.81 | CSF1R (0.70) | MAPTKCNK3KCNK9KCNQ3KCNQ2 | |
| SCHEMBL22088439 | 0.81 | MEN1 (0.70) | MAPTKCNK3KCNK9KCNQ3KCNQ2 | |
| SCHEMBL5504593 | 0.81 | MAPT (0.66) | MAPTKCNK3KCNK9KCNQ3KCNQ2 | |
| SCHEMBL2495506 | 0.81 | MAPT (0.61) | MAPTKCNK3KCNK9KCNQ3KCNQ2 | |
| SCHEMBL5131380 | 0.80 | RHOC (0.80) | MAPTKCNK3KCNK9KCNQ3KCNQ2 | |
| SCHEMBL4286068 | 0.80 | MAPT (0.94) | MAPTKCNK3KCNK9KCNQ3KCNQ2 | |
| SCHEMBL17936112 | 0.80 | MAPT (0.60) | MAPTKCNK3KCNK9KCNQ3KCNQ2 | |
| SCHEMBL14445616 | 0.80 | CSF1R (0.61) | MAPTKCNK3KCNK9KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008008234-A1 | 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | MAPT 3282/4885KCNK3 2376/4885KCNK9 1780/4885 |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | MAPT 3941/4885KCNK3 2714/4885KCNK9 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.